<DOC>
	<DOCNO>NCT02418845</DOCNO>
	<brief_summary>The purpose clinical trial test safety efficacy oral investigational new drug , SYM-1219 treatment bacterial vaginosis .</brief_summary>
	<brief_title>A Phase 3 Study SYM-1219 Treatment Women Post-Menarchal Adolescent Girls With Bacterial Vaginosis</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<criteria>Are premenopausal adult female post menarchal adolescent girl ≥12 year age good general health Have clinical diagnosis bacterial vaginosis , define follow criterion : Offwhite ( milky gray ) , thin , homogeneous vaginal discharge Vaginal pH ≥ 4.7 Presence Clue cell ≥ 20 % total epithelial cell microscopic examination vaginal saline wet mount A positive 10 % KOH Whiff test Have Gram stain slide Nugent Score ≥ 4 Baseline Visit ( Day 1 ) Are pregnant , lactating , plan become pregnant study Are menstruate vaginal bleeding Baseline Visit ( Day 1 ) Are suspect clinically ( confirm diagnostically ) alternative cause vaginal symptom include candidiasis , Chlamydia trachomatis , Trichomonas vaginalis , Neisseria gonorrhoeae Herpes simplex Have receive antifungal antimicrobial therapy ( systemic intravaginal ) within 14 day prior Baseline Visit ( Day 1 )</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>